Ashurst advises sellers on sale of Sividon Diagnostics to Myriad Genetics
Ashurst advised the sellers on the disposal of Sividon Diagnostics GmbH (Sividon Diagnostics), a leading German breast cancer prognostic test developer, to Myriad Genetics. NASDAQ listed Myriad Genetics is a leader in molecular diagnostics and personalised medicine. Sividon was spun out of Siemens Healthcare Diagnostics in 2010 as part of a management buyout.
The purchase price amounts to up to €50 million (including earn-out).